CLAIMS

1. Use of a MAdCAM antagonist antibody in the manufacture of a medicament for the treatment of a patient susceptible to or diagnosed with ulcerative colitis, wherein the medicament is to be administered subcutaneously to the patient an initial dose of 22.5 mg or 75 mg of the MAdCAM antagonist antibody followed by one or more subsequent doses of the MAdCAM antagonist antibody in an amount that is about the same as the initial dose, wherein the one or more subsequent doses are dosed about every 4 weeks, wherein the MAdCAM antagonist antibody comprises a light chain CDR1 of SEQ ID NO:11; a light chain CDR2 of SEQ ID NO:12; and a light chain CDR3 of SEQ ID NO:13; and a heavy chain CDR1 of SEQ ID NO:14; a heavy chain CDR2 of SEQ ID NO:15; and a heavy chain CDR3 of SEQ ID NO:16, and wherein the observed clinical remission rate at about 12 weeks after initial dose, as determined using the MAYO score, is at least about 10%.

2. The use of claim 1, wherein a subsequent dose is to be administered in an amount that is about the same or less than the initial dose.

3. The use of claim 1 or 2, wherein one or more subsequent doses of 22.5 mg or 75 mg of MAdCAM antagonist antibody is to be administered to the patient.

4. The use of any one of claims 1-3, wherein the patient is not taking a TNF antagonist or TNF inhibitor.

5. The use of any one of claims 1-4, wherein the MAdCAM antagonist antibody comprises a variable light chain of SEQ ID NO:3, and a variable heavy chain of SEQ ID NO:4.

6. The method of any one of claims 1-5, wherein the MAdCAM antagonist antibody comprises a light chain of SEQ ID NO:1, and a heavy chain of SEQ ID NO:2.